Abstract 1653P
Background
The presence of minimal intra-pancreatic fat deposition (IPFD) in the healthy human pancreas has been demonstrated in numerous studies. But excess IPFD, leads to a wide array of diseases, including but not limited to diabetes, pancreatitis, and pancreatic cancer (PC). Remarkably, PC patients with excessive intra-pancreatic fat accumulation are commonly associated with a poor prognosis compared to those with minimal IPFD. However, the interaction between tumor and IPFD remains elusive. Here, we evaluated the pancreatic fat infiltration in normal people and patients with PC respectively, and explored how intra-pancreatic fat accelerates tumor progression.
Methods
Magnetic resonance imaging (MRI) and clinical biopsy specimens were used to assess the degree of pancreatic fat infiltration in PC patients and healthy control individuals. The KC, KPC, KCO, and AAV8-ADIPOQ-DTA mice were established to demonstrate that IPFD promoted tumor progression. The single-nucleus sequencing of pancreatic fat tissue and proteomic of PC cell lines were performed to identify the mechanism of interaction between cancer cells and adipocytes.
Results
We found that patients with PC presented excess intra-pancreatic fat deposition more frequently than control individuals, and the degree of fat infiltration was positively correlated with the tumor size of PC patients. High-fat diet KPC mice or KCO mice showed a higher degree of IPFD, which contributed to tumor growth and low survival rates of mice. Besides, the expression of uncoupling protein 1 (UCP1) was upregulated in PC patients or spontaneous tumor mice compared to normal controls. Constantly, the single-nucleus sequencing of pancreatic fat tissue of PC patients demonstrated the increase in thermogenesis features. Specifically, we revealed that PC cells improved the thermogenesis of intra-pancreatic adipose tissue, which in turn promoted PC cell proliferation.
Conclusions
We demonstrated that excess intra-pancreatic fat infiltration fuels the progression of PC, and selectively eliminating fat in the pancreas inhibits tumor growth. Mechanistically, PC cells promote the browning of adipocytes, and then the activated adipocytes enhance the proliferation and migration of cancer cells in response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
PUMCH.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22